A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
Clinical trial NCT00002016 · COMPLETED
Trial details
- NCT number
- NCT00002016
- Sponsor
- Sandoz
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.